Patent details

Basic Information

Publication number:

EP2047867

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Expired

Application number:

EP080192495

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

ACE2 activation for treatment of heart, lung and kidney disease and hypertension

French Title of Invention:

Activation d'ACE2 pour le traitement de maladies du coeur, des poumons et des reins et de l'hypertension

German Title of Invention:

ACE2-Aktivierung zur Behandlung von Herz-, Lungen- und Nierenkrankheiten und Hochdruck

SPC Number:

Dates

Filing date:

19/06/2003

Grant date:

22/05/2013

EP Publication Date:

22/05/2013

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

15/04/2009

EP B1 Publication Date:

22/05/2013

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

19/06/2023

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

19/06/2003

 

 

Name:

Apeiron Biologics AG

Address:

Campus-Vienna-Biocenter 5, 1030 Wien, Austria (AT)

Agent

Name:

KIRKPATRICK

From:

19/07/2013

Address:

AVENUE WOLFERS 32, 1310, LA HULPE, Belgium (BE)

To:

Inventor

1

Name:

Penninger Joseph M

Address:

Austria (AT)

2

Name:

Crackower Michael A.

Address:

Canada (CA)

Priority

Priority Number:

389709 P

Priority Date:

19/06/2002

Priority Country:

United States (US)

Classification

Main IPC Class:

A61K 48/00;

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

21/06/2022

Last Annual Fee Paid Number:

20

Last Annual Fee Paid Amount:

300 Euro

Payer:

PAVIS GMBH

Filing date	Document type	Number of pages